MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.20
+1.15 (+10.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.05
Open11.50
Bid6.05 x 1100
Ask0.00 x 800
Day's Range11.47 - 12.35
52 Week Range5.75 - 14.50
Volume127,102
Avg. Volume94,271
Market Cap510.925M
Beta0.65
PE Ratio (TTM)N/A
EPS (TTM)-0.34
Earnings DateApr 26, 2017 - May 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire16 days ago

    MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global Healthcare Conference which will be held at the Grand Hyatt New York in New York City from September 12 - 14, 2018. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire22 days ago

    MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine

    LA JOLLA, Calif., Aug. 29, 2018-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the New England ...

  • GlobeNewswirelast month

    National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder

    MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is part of the National Institutes of Health (NIH), will fund a Phase 2b clinical trial to evaluate MN-166 (ibudilast) as a potential treatment to decrease alcohol consumption in treatment-seeking patients with alcohol use disorder (AUD).  This study is a randomized, double-blind, placebo-controlled outpatient trial which will enroll up to 132 patients.

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, ...

  • GlobeNewswirelast month

    MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of MN-166 (ibudilast) in degenerative cervical myelopathy (DCM) in collaboration with the University of Cambridge. This clinical trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust.

  • GlobeNewswire2 months ago

    MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK

    The oral presentation entitled "Novel Composite Endpoint Extended Analysis during Extension of Ibudilast Phase 1b/2a Clinical Trial Better Predicts Post-Wash-Out Survival” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.

  • GlobeNewswire2 months ago

    MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) is now fully enrolled with 35 subjects. This trial will measure the effect of MN-166 (ibudilast) on reducing brain microglial activation measured by positron emission tomography (PET) imaging using a biomarker and will also evaluate clinical outcomes in ALS subjects. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that this study is now fully enrolled.

  • Zacks Small Cap Research2 months ago

    MNOV: Plenty of Cash to Advance Pipeline Forward

    On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.

  • Zacks Small Cap Research2 months ago

    MNOV: Encouraging Data from Subgroup Analysis of ALS Study

    This group was comprised of 31 subjects out of a total of 49 subjects in the full analysis set. A second subgroup comprised of 39 subjects (out of a total of 67 subjects in the full analysis set) who had either bulbar onset or upper limb onset ALS with or without NIV (the “Early ALS + NIV subgroup”). The score is utilized to keep track of the health of all ALS patients, and is a common outcome measure in ALS clinical trials.

  • GlobeNewswire2 months ago

    MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS

    The ad-hoc subgroup analyses include data from (1) the “Early ALS subgroup” which is 31 subjects who had either bulbar onset or upper limb onset out of a total of 49 subjects without non-invasive ventilation in the full analysis set and (2) the “Early ALS + NIV subgroup” which is 39 subjects who had either bulbar onset or upper limb onset out of a total of 67 subjects with and without non-invasive ventilation in the full analysis set. The full analysis set includes all randomized subjects who received at least 14 days of study drug and had at least one post-dose efficacy measurement.

  • When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?
    Simply Wall St.4 months ago

    When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable?

    MediciNova Inc’s (NASDAQ:MNOV): MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in theRead More...

  • Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately
    Simply Wall St.4 months ago

    Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately

    After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...

  • Zacks Small Cap Research5 months ago

    MNOV: Additional Data Presented for MN-166 in MS and ALS

    MediciNova, Inc. (MNOV) recently had additional data presented on one of its lead compounds, MN-166 (ibudilast), in two different indications at the American Academy of Neurology (AAN) 70th Annual Meeting. Progressive Multiple Sclerosis (MS): Dr. Robert Fox, the principal investigator of the completed Phase 2 SPRINT-MS trial, gave a presentation titled “A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis”. Included in the presentation was the previously announced data showing that treatment with MN-166 resulted in a 48% reduction in the rate of whole brain atrophy progression.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Financial Select Sector SPDR Fund (NYSE: XLF ) stock ...

  • Benzinga6 months ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...